The Side-Effect List You've Read Was Never Actually Measured
Almost every Amanita microdosing page carries the same tidy list: mild drowsiness, slight nausea, extra salivation, vivid dreams. It reads like something copied off a drug label. It isn't. In September 2024 the FDA published a scientific memorandum concluding that no toxicity studies sufficient to establish safe food use of Amanita muscaria, muscimol, ibotenic acid or muscarine exist in the literature — and that the available research doesn't even characterise how the compounds are absorbed, distributed, metabolised and excreted in humans (FDA Scientific Memorandum, 2024).
That decides what the rest of this article can honestly say. No dose-ranging trial. No adverse-event table from a controlled study. Nothing that could produce a validated side-effect profile at any dose, let alone a small one.
So where does the tidy list come from? From people describing their own low-dose experiences, and from working backwards out of poisoning cases. Both are real information; neither is a side-effect profile. What we do have is an adverse-event record — poison-centre calls, hospital case reports, regulatory complaint databases — and it says several things the tidy list leaves out.
What the Adverse-Event Record Actually Contains
The FDA queried America's Poison Centers' National Poison Data System across three product-code groups covering muscimol- and ibotenic-acid-containing mushrooms and processed Amanita preparations; the queries returned 695, 57 and 155 cases. Reported effects included hallucinations, hypertension, tachycardia, seizures, CNS depression, coma, respiratory depression and death, with hospitalisation, intubation and critical care all represented (FDA Scientific Memorandum, 2024).
The most useful single dataset is smaller and more granular. Moss and Hendrickson reviewed 15 years of ingestions reported to a US regional poison centre: 34 cases, of which 23 were A. muscaria. Among the muscaria cases, gastrointestinal symptoms, CNS depression and CNS excitation each appeared in about 35% of patients. Five patients across the series required intubation. There were no deaths, no seizures, no kidney injury and no liver damage, and most symptomatic patients declared themselves within six hours (Moss & Hendrickson, Clinical Toxicology, 2019).
Two things fall out of those numbers. The first is that excitation is as common as sedation. Popular framing treats fly agaric as a downer, so agitation, racing heart and confusion get read as "bad batch" when they're simply the other expected direction. The second is that the same review found A. pantherina markedly more symptomatic than A. muscaria on every axis — 80% versus 35% for GI effects, 70% versus 35% for both CNS categories. Species is not a detail.
Now the caveat, because it cuts both ways. Poison-centre data records the calls people make. Nobody phones a poison centre about mild drowsiness, so the dataset skews toward the severe end and cannot tell you how often a small dose passes uneventfully. It isn't a frequency table for microdosing. It's a catalogue of what this mushroom is capable of — which is the part the tidy list omits.
Why the Gap Between "Effect" and "Emergency" Is Narrower Than It Looks
The clearest quantitative signal on margin comes from animal work. In male mice given muscimol intraperitoneally, the median neurotoxic dose (TD50) was 0.65 mg/kg and the median lethal dose 8.1 mg/kg — roughly twelve-fold between the dose that visibly impairs and the dose that kills half the animals (Löscher 1982, cited in the FDA Scientific Memorandum, 2024). That's a mouse, injected; it should not be converted into a human number. But twelve-fold is a narrow corridor for any compound, and nothing in the literature suggests the human corridor is dramatically wider.
Set that against the dosing reality. Muscimol and ibotenic acid concentrations vary between caps, between tissues within one cap, and between batches — which is why preparing Amanita for microdosing is a sampling problem rather than a recipe. A narrow corridor plus an unmeasured input is the actual risk structure here. Not "mild side effects, occasionally."
The second case in Meisel's report makes the point without any extrapolation at all: a 75-year-old man who accidentally ate one large foraged cap presented with hallucinations and lethargy, required intubation, and recovered fully (Meisel et al., Wilderness & Environmental Medicine, 2022). One cap. Age and individual sensitivity clearly matter, and no product label accounts for either.
Onset Is Slow Enough That People Take a Second Dose — and Effects Can Outlast the Day
Symptom onset after A. muscaria ingestion is documented at 30 minutes to 2 hours (FDA Scientific Memorandum, 2024), and severe courses can begin far later than that. In the fatality reported by Meisel and colleagues, a 44-year-old man suffered cardiopulmonary arrest roughly ten hours after ingesting four to five dried caps; he was resuscitated but never regained responsiveness and died nine days later (Meisel et al., Wilderness & Environmental Medicine, 2022).
A two-hour window is the single most practically dangerous fact on this page. It's long enough for someone who feels nothing at forty minutes to conclude the dose was too small and take more — then receive both doses at once, on the steep part of the curve. From what we've seen across these accounts, that re-dosing decision, not the original dose, is what turns a quiet evening into a hospital story. The countermeasure is unglamorous: fix the dose before you take it, and treat "I don't feel anything yet" as expected information rather than a reason to act.
Duration is understated in the same way. The FDA's review summarises case reports of delirium, hallucinations and paranoid psychosis persisting up to five days, and a 72-hour coma requiring intubation in an accidental poisoning (Rampolli et al., 2021, as summarised in the FDA memorandum). Those are severe-end cases and a small dose isn't the same event — but they say something that scales downward: the effect doesn't reliably end when the user expects it to. Anyone planning to drive, work or supervise a child that day is planning around a duration nobody has characterised at low doses. That rules out the "take it before work" pattern microdosing culture inherited from psilocybin, and the two practices are less alike than the shared word suggests, as our piece on why "microdosing" means something different for Amanita sets out.
A Large Share of Reported "Amanita Side Effects" May Not Be Amanita at All
This is the finding that should reorganise how you read every side-effect report online, and it's the least discussed. When investigators have actually put commercial Amanita products through a mass spectrometer, the label has repeatedly turned out to be wrong about what's inside.
In a 2025 analysis of eight mushroom gummy products bought from seven smoke and vape shops in Portland, Oregon, seven of the eight contained psilocin and six contained 4-acetoxy-DMT. One product advertised as "psilocybin-free" tested positive for psilocybin. Critically, the two products claiming Amanita muscaria extract contained psilocin and tryptamine derivatives — with no muscimol or ibotenic acid detected at all (Correia et al., Clinical Toxicology, 2025).
A CDC field investigation in Charlottesville, Virginia found the same pattern. Of six packages representing five brands of Amanita-labelled "nootropic" gummies, four contained undisclosed Schedule I substances — psilocybin or psilocin — alongside unlabelled caffeine, ephedrine, mitragynine, hordenine and DMT. Five patients, including a three-year-old, required hospital evaluation between September 2023 and June 2024 (Michienzi et al., MMWR, 2024;73(28):628–630).
Then the outbreak that made the category visible. Diamond Shruumz edibles, explicitly marketed for microdosing, were linked to 180 illnesses across 34 states, 73 hospitalisations and three deaths in the FDA's final November 2024 tally. Testing found muscimol — but also acetylpsilocin, psilocin, the prescription drug pregabalin and kavalactones, with different compounds in different flavours and variation even within one flavour (Food Safety News, reporting FDA findings, 2024).
So when a forum post reports seizures from "microdosing Amanita," the honest reading is that nobody knows what that person took. That's the practical argument for whole dried caps you can identify by eye, or a seller who will show you a certificate of analysis, over anonymous gummies — a single-ingredient dried Amanita muscaria cap is at least unambiguously the thing it claims to be. Not a safety guarantee. A smaller unknown.
Who Carries the Most Risk — and What Nobody Has Studied
The FDA's memorandum is explicit that the evidence cannot support safety for the general population "including vulnerable subpopulations such as pregnant individuals/conceptus/fetus, infants, and young children, considering lifetime exposure," and that no study evaluated neurotoxicity, developmental toxicity or chronic toxicity endpoints (FDA Scientific Memorandum, 2024). In December 2024 the agency added Amanita muscaria to its inventory of substances determined not to be Generally Recognized as Safe, calling its constituents unapproved food additives whose use in food may be harmful.
Several groups carry clearly higher risk, and none of this is controversial:
- Children and pets. The literature includes paediatric cases with coma and respiratory arrest, and the Charlottesville cluster included a three-year-old. Gummies are the worst possible format for either household.
- Anyone taking CNS depressants. Muscimol is a GABA-A agonist. Combining it with alcohol, benzodiazepines, z-drugs, opioids or sedating antihistamines stacks the same mechanism, and no interaction study exists to say by how much.
- Pregnancy and breastfeeding. No developmental toxicity data, and so no dose with an established margin — small or otherwise.
- Anyone driving or working that day. Duration is uncharacterised at low doses, and the sedation is real.
- People managing a diagnosed condition. Amanita is not an established treatment for anxiety, insomnia, ADHD or depression. Using it in place of care that has actually been tested is the substitution with the worst expected value, and that conversation belongs with a clinician.
What Actually Warrants Stopping and Calling for Help
The original version of this article listed four warning signs with no grounding behind them. Here's the grounded version, drawn from the symptom clusters that recur across the case literature and poison-centre reviews above. Seek medical care — don't wait it out — for seizure activity or twitching that won't stop; loss of consciousness or a person who can't be roused; slow, shallow or irregular breathing; confusion or agitation severe enough to make the person unsafe; persistent vomiting; or an obviously abnormal heart rate, blood pressure or temperature.
Two practical notes. Tell the clinician exactly what was taken and bring the packaging or a remaining cap if you can — given the adulteration findings above, "an Amanita gummy" may not be the useful answer. And treatment is supportive: there's no antidote, which is exactly why the threshold for calling should be low rather than heroic.
Is any of this an argument that nobody should ever take a small dose? No. It's an argument that the risk is structural — an unmeasured input, a narrow corridor, a slow onset, an unreliable supply chain — rather than a short list of mild inconveniences. The identification and safety basics in our fly agaric facts, risks and safe-use guide are the reasonable next step for anyone weighing it.
Frequently Asked Questions
What are the actual side effects of microdosing Amanita muscaria?
No study has ever measured them. The commonly published list — drowsiness, mild nausea, salivation, vivid dreams — comes from self-report, not research. The FDA's 2024 review found no toxicity studies adequate to establish safe use and no characterised human absorption or metabolism profile, so any low-dose side-effect list should be read as inference rather than data.
How long after taking Amanita muscaria do side effects start?
Documented onset is 30 minutes to 2 hours, and severe presentations can begin much later — the fatality reported by Meisel et al. involved cardiopulmonary arrest around ten hours post-ingestion. The practical consequence is that feeling nothing at the 40-minute mark tells you very little, and re-dosing on that basis is how many bad outcomes begin.
Can a small dose of Amanita muscaria cause agitation rather than sedation?
Yes, and it's expected rather than anomalous. A regional poison-centre review sorted A. muscaria symptoms into three categories: gastrointestinal effects, CNS depression from muscimol, and CNS excitation from ibotenic acid. Clinicians also describe alternating stimulation and depression within one episode, so agitation is not evidence of a bad batch.
Are Amanita muscaria gummies safer than dried caps?
The testing evidence points the other way. In a 2025 Portland analysis, both products claiming Amanita extract contained psilocin and tryptamines with no muscimol detected, and a CDC investigation found undisclosed Schedule I substances in four of six Amanita-labelled gummy packages. A dried cap is at least unambiguously what it claims to be.
Does Amanita muscaria interact with alcohol or sleep medication?
Muscimol is a GABA-A agonist, the same broad mechanism alcohol, benzodiazepines, z-drugs and sedating antihistamines act on, so combining them stacks effects on one system. No human interaction study exists to quantify the risk, which means the size of the interaction is unknown rather than small. Treat the combination as one to avoid.
Who should not take Amanita muscaria at all?
Children, anyone pregnant or breastfeeding, anyone taking CNS depressants including alcohol, anyone driving or working that day, and anyone substituting it for treatment of a diagnosed condition. The FDA's review specifically noted the absence of developmental, neurotoxicity and chronic-toxicity data covering vulnerable groups.
The Bottom Line
The side-effect list that circulates for Amanita microdosing isn't wrong so much as unmoored — it describes what people report, in a space where nobody has measured anything. The evidence that does exist points at a different shape of risk: a roughly twelve-fold corridor between impairment and lethality in animal work, potency that varies cap to cap, an onset slow enough to invite re-dosing, effects that have run for days in case reports, and a retail supply chain where testing keeps finding compounds other than the one on the label.
None of that requires panic. It requires taking the unknowns seriously enough to fix a dose in advance, keep the product away from children, avoid stacking it with anything sedating, and recognise a real emergency. That's a lower bar than most wellness content sets — and a much higher one than four bullets about mild inconveniences.
Written by Viktor, who runs Amanita Store and spends more time reading toxicology case reports than is probably normal. This article is educational and is not medical advice. Amanita muscaria is not an approved food ingredient in the United States and is not a treatment for any condition. If you are managing anxiety, insomnia, ADHD or depression, talk to a clinician.